p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7328-7333

  Xu, Ye ^a   Yao, Lihua ^a   Ouyang, Tao ^a   Li, Jinfeng ^a   Wang, Tianfeng ^a   Fan, Zhaoqing ^a   Lin, Benyao ^a   Lu, Youyong ^a   Xie, Yuntao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PIRARUBICIN; PROGESTERONE RECEPTOR; PROLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CODON; CONFIDENCE INTERVAL; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CODON; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

EID: 27144536311     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0507     Document Type: Article

References (23)

1. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004;10:3249-61.
2. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003;97:1758-65.
3. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997;349:849.
4. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
5. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
6. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
7. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
8. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.
9. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998;352:871-2.
10. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
11. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
12. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
13. Nilsson G, Skytting B, Xie Y, et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 1999;59:3180-4.
14. Soong R, Iacopetta BJ, Harvey JM, et al. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 1997;74:642-7.
15. Powell BL, Bydder S, Grieu F, et al. Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Res Treat 2001;69:65-8.
16. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6.
17. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-73.
18. Geisler S, Borresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-8.
19. Langerod A, Bukholm IR, Bregard A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11:1684-8.
20. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
21. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
22. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471-9.
23. Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998;79:27-33.